Sun Pharma & Hikma enter deal for plaque psoriasis drug in MENA region

On Monday, Sun Pharma announced that one of its wholly-owned subsidiaries entered into an exclusive licensing and distribution agreement with Hikma Pharmaceuticals PLC (Hikma) for Ilumya, a plaque psoriasis medicine, in the Middle East & North Africa (MENA) region.

Authorized in 2018 by United States Food and Drug Administration (USFDA), Ilumya is an antibody used for treating adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Hikma Pharmaceuticals, which has a strong presence in the region, will take charge of registration and commercialization of the product in all MENA markets while Sun Pharma will be responsible for product supply under the terms of the agreement. The total duration of the contract will be for 15 years from the point of first sale, with two years automatic renewal periods.

Sun Pharma Laboratories Limited (SPLL) offers pharmaceutical services worldwide and extends generic, speciality, over-the-counter (OTC) products, active pharmaceutical ingredients (APIs), antiretrovirals (ARVs) and intermediates.

On Monday, the stock of the company closed at Rs 485.45, up by 1.18 per cent or Rs 5.65 per share on Friday. The 52-week high is recorded at Rs 512.55 and the 52-week low is Rs 315.20 on BSE.